GENELABS TECHNOLOGIES INC Contracts & Agreements
20 Contracts & Agreements
- Business Finance (4 contracts)
- Business Operations (2)
- Human Resources (3)
- Uncategorized (11)
- Entry into a Material Definitive Agreement (Filed With SEC on November 3, 2008)
- Entry into a Material Definitive Agreement (Filed With SEC on November 3, 2008)
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (Filed With SEC on October 30, 2008)
- SEPARATION AGREEMENT ANDGENERAL RELEASE (Filed With SEC on February 11, 2008)
- Form of Warrant THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 4 OF THIS WARRANT (Filed With SEC on September 26, 2007)
- our ability to secure sufficient funds as a going concern (Filed With SEC on August 13, 2007)
- our ability to secure sufficient funds as a going concern (Filed With SEC on May 14, 2007)
- FORM OF SECURITIES PURCHASE AGREEMENT (Filed With SEC on February 14, 2007)
- our ability to remain listed on the Nasdaq Capital Market (Filed With SEC on August 3, 2006)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on July 3, 2006)
- Dr. Ahmeds employment with Genelabs terminated on June 15, 2006 (Filed With SEC on June 19, 2006)
- Dr. Ahmeds employment with Genelabs terminated on June 15, 2006 (Filed With SEC on June 19, 2006)
- our ability to secure sufficient funds to continue as a going concern (Filed With SEC on March 31, 2006)
- our ability to secure sufficient funds to continue as a going concern (Filed With SEC on March 31, 2006)
- our ability to secure sufficient funds to continue as a going concern (Filed With SEC on March 31, 2006)
- results and analysis of our recent Prestara Phase III clinical trial in the United States and the follow-on open label clinical trial (Filed With SEC on November 4, 2004)
- estimates relating to the timing and completion of our pending clinical trials (Filed With SEC on May 7, 2004)
- estimates relating to our cash resources and our ability to obtain additional funding for our business plans (Filed With SEC on August 13, 2003)
- potential FDA actions with respect to our NDA for Prestara (formerly Aslera or GL701), including whether or not the Prestara NDA ultimately will receive marketing approval and the... (Filed With SEC on November 14, 2002)
- potential FDA actions with respect to our NDA for Prestara (formerly Aslera or GL701), including whether or not the Prestara NDA ultimately will receive marketing approval and the... (Filed With SEC on November 14, 2002)
